XERS250117C1500
- 1.60
- 0.000.00%
Xeris Pharmaceuticals Newsroom
Craig-Hallum Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Announces Target Price $5
Xeris Biopharma Price Target Maintained With a $3.00/Share by Piper Sandler
Xeris Biopharma Holdings Analyst Ratings
H.C. Wainwright Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Raises Target Price to $6.6
Xeris Pharmaceuticals: Hold Rating Amid Growth and Cost Concerns
Craig-Hallum Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating
Craig-Hallum Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating
Craig-Hallum Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating
Craig-Hallum Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating
Craig-Hallum Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating
Xeris Pharmaceuticals (XERS) Gets a Buy From Craig-Hallum
Oppenheimer Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Maintains Target Price $5
Oppenheimer Remains a Buy on Xeris Pharmaceuticals (XERS)
Xeris Biopharma Holdings Analyst Ratings
H.C. Wainwright Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Maintains Target Price $6
Analysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (XERS), Aldeyra Therapeutics (ALDX) and Immunic (IMUX)
Oppenheimer Reaffirms Their Buy Rating on Xeris Pharmaceuticals (XERS)
Craig-Hallum Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating
Craig-Hallum Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating
Xeris Pharmaceuticals (XERS) Gets a Buy From Craig-Hallum